The week’s relief trade just hit a wall. Overnight the US–Iran peace process stumbled: the nuclear talks due to open in Switzerland this weekend were postponed after fighting in southern Lebanon escalated to its worst since the April ceasefire, and Tehran — which made a Lebanon truce a condition of the interim deal — withheld its delegation. Oil ticked back up (Brent near $80, WTI ~$77), stocks stalled, and the dollar stayed firmly bid: Kevin Warsh’s hawkish Fed drove EUR/USD to ~1.14, its lowest since March, and the dollar index to a 13-month high, with markets now pricing roughly an 88% chance of a December rate hike. US cash markets were shut Friday for Juneteenth — the last print is Thursday’s close (S&P 7,500.58, Nasdaq 26,517.93) — and reopen Monday.
Weekend edition. Equity indices are Thursday 18 June’s closes (US stock & bond markets were shut Friday 19 for Juneteenth and reopen Monday 22); FX, gilts, crude and gold reflect Friday’s European session and the live overnight read. The swing factors into Monday: whether US–Iran talks get a new date or Lebanon deteriorates further, the durability of post-Warsh rate-hike pricing, and oil’s response to the Hormuz/Lebanon headlines.
Top of the morning
US–Iran talks postponed as Lebanon clashes escalate — the relief trade’s first real setback
The nuclear and peace negotiations meant to begin in Switzerland this weekend were delayed after southern Lebanon flared into the worst fighting since April; Iran, which insisted on a Lebanon ceasefire as part of the interim accord, did not send a delegation, and Vice-President JD Vance shelved his trip. Israel said four soldiers, including a battalion commander, were killed; Trump has reportedly clashed with Netanyahu over strikes that nearly scuppered the 17 June memorandum. President Pezeshkian says Tehran has not abandoned talks, but no new date is set — and the 60-day clock to a formal end keeps running.
Dollar hits a 13-month high as Warsh’s hawkish Fed bites
EUR/USD fell to ~1.1417, its lowest since March, and the dollar index touched 100.80 — its strongest since May 2025 — after the first FOMC under Kevin Warsh dropped the easing bias and tilted its dots toward a hike; nine of nineteen policymakers now see at least one rise in 2026, and futures put December-hike odds near 88%. US stocks last printed Thursday before the holiday (S&P 500 +1.08% at 7,500.58, Nasdaq +1.91% at 26,517.93) and reopen Monday; gold slid ~1.7% to about $4,137.
Oil turns back up as the Hormuz/Lebanon risk re-enters
After a week spent pricing a coming glut as the Strait reopened, crude reversed higher once the Switzerland talks were called off — Brent steadied near $80 and WTI near $77, both up on the day. The war premium isn’t fully gone. The disinflationary dividend is still visible elsewhere: FT reports fertiliser and urea prices have tumbled back to prewar levels as traders look past the Middle East disruption — though the parallel drop in demand, it notes, “is not good news.”
Burnham’s win rattles gilts as UK borrowing hits a post-2019 high
Ten-year gilt yields rose more than seven basis points to ~4.82% on Friday after data showed May government borrowing of £23.3bn, the highest for the month since 2019. Andy Burnham’s Makerfield by-election win returns him to Parliament and opens a Labour leadership challenge to Keir Starmer; FT reports his camp is already divided over a chancellor pick (Miliband, Mahmood, Cooper) as bond markets seek reassurance. A slow-burn fiscal-risk premium is building into UK duration.
Washington opens a tariff probe of Germany over drug pricing
The US has launched a Section 301 investigation into Germany’s spending on new medicines, alleging persistent underpayment for innovative drugs — a sharp escalation of the transatlantic pricing fight that Chancellor Merz is pushing back on, citing the EU trade pact. For the pharma complex it layers a policy overhang onto European price-setting just as the sector navigates US most-favoured-nation pressure — a theme worth watching for any branded-drug holding.
Europe blinks on China; hardens its financial borders
EU leaders in Brussels chose to delay a trade confrontation with Beijing, favouring dialogue over immediate action on imbalances for fear of retaliation, while moving to strip away barriers to banks’ cross-border capital flows to close the performance gap with US rivals. Australia, meanwhile, faces a 55% China tariff on beef as a quota fills — the same fault lines, viewed from the commodity end.
The AI float wave builds — OpenAI files, SpaceX plots a $20bn bond
OpenAI has filed for an IPO and Anthropic-listing chatter is swirling, even as Washington tightens foreign access to advanced models (Commerce’s Lutnick crackdown) and Trump tells Axios he doesn’t see Anthropic as a US security threat. SpaceX is preparing a debt deal of at least $20bn after its record IPO, and DeepMind’s Nobel laureate John Jumper is decamping to Anthropic. A capex-and-capital-markets wave with policy strings attached.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. Higher-for-longer is firmly back in the driver’s seat. Rates are the dominant signal: Warsh’s hawkish hold — easing bias gone, dots tilted to a hike, December odds ~88% — lifted the dollar to a 13-month high (EUR/USD ~1.14, cable ~1.34) and argues for continued duration caution. FT’s Katie Martin (“Markets get the measure of Trump”) makes the two-way point sharply: investors now pounce the moment the president looks to be buckling on a foreign-policy stance — relevant the instant the Iran deal started to wobble overnight. The energy offset is real but no longer one-way: FT still frames crude as a coming glut (Brent under $80, fertiliser back to prewar levels), yet the Lebanon flare-up put a bid back under oil. The credit/regime flag for your war-chest discipline stays amber, not red: froth in AI-linked and private credit is visible, but there’s no severe systemic trigger today. Net: stance stays neutral-to-defensive, war-chest rules sheathed.
Healthcare / pharma (Novo Nordisk, Eli Lilly, Vertex, UnitedHealth, Thermo Fisher — theme + Novo single name). Two flags. Novo Nordisk’s owner, Novo Holdings, is opening obesity-drug incubators across Europe — doubling down on the GLP-1 ecosystem and pipeline optionality. And the US Section 301 probe into Germany’s drug pricing escalates the transatlantic pricing war, an overhang on European branded-drug economics. Separately, UnitedHealth’s $3bn AI push (bots calling doctors) is an efficiency play carrying execution and PR risk. No GLP-1 trial readout today — the clinical action is in the desk below.
AI capex & cloud (Microsoft, Alphabet, Amazon, Broadcom — theme). Demand is intact; the funding mix and policy overhang are the watch-items. OpenAI has filed to IPO, SpaceX is plotting a ≥$20bn bond after its record debut, and Anthropic-listing talk is live — a capex wave leaning ever harder on credit. The counter-signal is policy: Commerce is tightening foreign access to frontier models, an export-control thread now running through the whole AI stack.
Semiconductors (ASML, Broadcom — theme). The recurring single-name overhang persists: the US has again told ASML it is concerned China may already have its most advanced chip tool — an export-control cloud over the lithography monopoly and the AI-hardware chain. Watch for any ASML or Commerce follow-through.
Payments (Visa, Mastercard) · slow-burn risk. Bloomberg’s Big Take again has Europe fighting to loosen America’s grip on payment systems and hunting alternatives to the US card networks on sovereignty grounds. No near-term catalyst, but a structural watch-item for the duopoly.
Berkshire / industrials (Caterpillar, Deere, Booking — quiet). No held-name items in today’s feed; the cyclical read is indirect — cheaper energy a cost tailwind, a firmer dollar a translation headwind, and a wobblier Iran deal a small risk back into freight and insurance.
Shelf single-names live today: Novo Nordisk (owner’s European obesity incubators) and ASML (US export-control concern over China access). Everything else is theme-level — an AI capex/IPO-supply watch, a US–Germany pharma-pricing probe, and a private-credit froth flag set against a hawkish Warsh Fed and a two-way oil tape.
Net: the relief trade stumbled overnight — talks delayed, Lebanon flaring, the oil bid back — but it’s a wobble, not a regime change, and no severe trigger fired. A hawkish Fed, a 13-month-high dollar and softer gold keep the regime neutral-to-defensive; war-chest rules stay sheathed. Watch-lines: a new US–Iran talks date (or further Lebanon escalation), post-Warsh rate-hike pricing and the 10-year, oil’s Hormuz response, the US–Germany pharma probe, and AI IPO/bond supply.
Markets snapshot
Read this morning from the live Bloomberg Europe page. Equity indices are Thursday 18 June closes (US shut Friday for Juneteenth); European indices, gilts, FX, crude and gold reflect Friday’s session and the overnight read.
+0.9% · bid back on cancelled talks; WTI ~$77 (+1.2%)
Gold (spot)
$4,136.59
−1.74% Fri · haven demand drains as hike bets firm
Levels read from the Bloomberg Europe page this morning and cross-checked via web search. The week’s signature is a split screen: a hawkish Warsh Fed keeping the dollar bid and gold heavy, set against a Gulf de-escalation that wobbled overnight as talks slipped and Lebanon flared, pushing oil back up. With the US shut Friday for Juneteenth, the next live Wall Street session is Monday 22.
Global markets & macro
The rates regime Kevin Warsh reset on Wednesday is still doing the heavy lifting. The Fed held but stripped out its easing bias, eliminated explicit forward guidance, and published projections in which at least one further hike is now the central case — a response to inflation pushed toward roughly double the 2% target by the spring energy shock. The market has internalised it: the dollar index sits at a 13-month high near 100.80, EUR/USD has slid to ~1.1417 (its weakest since March), sterling is ~1.34, and December-hike odds are around 88%. Gold is the clean casualty, down ~1.7% to about $4,137 as haven demand drains. US equities, last printing Thursday before the Juneteenth close, still managed a chip-led bounce (S&P +1.08%, Nasdaq +1.91%); Europe was heavier on Friday — the Stoxx 600 off 0.2%, the FTSE 100 down 0.35%, the CAC 40 down 0.55%, the DAX flat — with oil & gas the lone bright spot. The standout stress is the UK: ten-year gilt yields jumped more than seven basis points to ~4.82% after May borrowing hit £23.3bn, the highest for the month since 2019, with the Burnham leadership question adding a fiscal-risk premium that bond markets are watching closely.
The energy side met its first real test overnight. Crude, which spent the week pricing a coming glut as Hormuz reopened, turned back up — Brent steadied near $80 and WTI near $77 — once the Switzerland talks were postponed and southern Lebanon flared, a reminder that the war premium hasn’t fully bled out. Disinflation is still visible at the margins (FT notes fertiliser and urea prices have fallen back to prewar levels), but it is no longer a one-way street. Underneath the indices, the capital-markets plumbing keeps rewriting itself on credit: OpenAI has filed to go public, SpaceX is preparing a bond of at least $20bn after its record debut, and Anthropic-listing chatter is building — even as Washington tightens foreign access to frontier models. The confidence vote on compute is real, but it is concentrating risk in exactly the corner — private and AI-linked credit — that a higher-for-longer Fed makes more fragile.
Geopolitics & world news
The transactional peace in the Gulf wobbled. The nuclear and peace talks set to open in Switzerland this weekend were postponed after fighting in southern Lebanon escalated to its worst since the April ceasefire; Tehran, which made a Lebanon truce a condition of the interim deal, withheld its delegation, and Vice-President JD Vance shelved his trip. The clashes were unusually deadly — Israel reported four soldiers killed, including a battalion commander — and Trump has reportedly clashed with Netanyahu over strikes that nearly derailed the 17 June memorandum. President Pezeshkian insists Iran has not walked away, but no new date is set, the 60-day clock to a formal end keeps ticking, and shipping executives still warn the accord’s language could eventually let Tehran levy Hormuz transit fees once the interim period lapses.
Elsewhere the economic borders keep hardening even as the hot war cools. EU leaders in Brussels chose to delay a trade confrontation with China, favouring dialogue over retaliation while warning on imbalances, and moved to ease cross-border bank-capital flows to narrow the gap with US rivals; Washington escalated on a separate front with its Section 301 probe of Germany’s drug pricing. In Britain, Andy Burnham’s by-election win returns him to Parliament and opens a leadership challenge to Starmer just as gilts wobble. And a public-health line worth flagging for the medical reader: a deadly H5 avian-influenza strain is spreading globally, with a fresh outbreak reported in Australia — a reminder that the pandemic-surveillance dial is ticking up again. The clinical deep-dive follows.
Clinical desk · NEJM this week
For the medical reader
Read this morning from the pinned NEJM current-issue eTOC feed (Vol 394, No 23, 18 June 2026), which this week also carries the ahead-of-print queue — a notably cardiology- and trials-heavy run spanning structural and interventional cardiology, pulmonology, nephrology, infectious disease, trauma and a first-in-class genetic-epilepsy therapy. The RSS carries only titles, so each result below was looked up against the NEJM abstract and conference/registry coverage; numbers are summarised, not reproduced.
TETON-2 — inhaled treprostinil in IPF (positive; practice-changing). In 597 patients with idiopathic pulmonary fibrosis (FVC ≥45% predicted), inhaled treprostinil beat placebo on the primary endpoint: FVC at week 52 was +95.6 mL higher (95% CI 52–139; P<0.001), reflecting a −49.9 mL decline on drug versus −136.4 mL on placebo — roughly halving the rate of lung-function loss. Cough (48% vs 24%) was the main tolerability cost, and the companion TETON-1 trial also met its primary endpoint. Takeaway: the first inhaled prostacyclin to slow progression in IPF — a potential third pillar alongside the two antifibrotics, and the issue’s most consequential readout for respiratory practice.
ODYSSEY-HCM — mavacamten in nonobstructive HCM (negative; important). A phase 3, placebo-controlled trial in symptomatic nonobstructive hypertrophic cardiomyopathy (LVEF ≥60%) over 48 weeks. The cardiac myosin inhibitor missed both co-primary endpoints — no significant improvement in peak VO₂ or in patient-reported health status — despite clear biology (lower NT-proBNP, modest reverse remodelling). Takeaway: “biology improved, patients did not.” Mavacamten stays confined to the obstructive phenotype, and nonobstructive HCM remains without a disease-modifying drug.
Prehospital whole blood in traumatic haemorrhage — SWiFT and a companion RCT (neutral/negative; landmark pairing). The UK SWiFT trial randomised 616 patients with life-threatening traumatic bleeding to up to two units of prehospital whole blood versus standard components. The 24-hour composite of death or massive transfusion was essentially identical — 48.7% vs 47.7% (RR 1.02, 95% CI 0.80–1.31; P=0.84) — with mortality numerically no better on whole blood at any timepoint. Published alongside a concordant US trial of prehospital type O whole blood; the editorial calls the evidence “consistent.” Takeaway: a cold-water result for prehospital whole-blood momentum — logistics and cost now have to justify themselves against no demonstrated survival edge.
ALL-RISE — angiography-derived FFR to guide PCI (positive; cath-lab relevant). In patients with intermediate coronary lesions, a wire-free angiography-derived physiology strategy (FFRangio) was noninferior to pressure-wire FFR for the one-year composite of death, MI or unplanned revascularisation — while cutting contrast use, radiation and procedure time. Takeaway: credible support for wire-free physiology in the cath lab, easing a practical barrier to guideline-directed lesion assessment.
APPLAUSE-IgAN — iptacopan, final 24-month data (positive; nephrology). The oral factor B inhibitor (alternative-complement pathway) in 478 patients with IgA nephropathy on supportive care. Proteinuria fell 38.3% versus placebo at nine months, and the benefit carried through to hard outcomes by 24 months: a composite kidney-failure event in 21.4% on iptacopan vs 33.5% on placebo, with a significantly slower eGFR decline and comparable safety. Takeaway: durable kidney protection validates complement-pathway targeting in IgAN.
Cefazolin for MSSA bacteraemia — platform trial (positive; stewardship). Within an international Bayesian adaptive platform trial, adults with methicillin-susceptible S. aureus bacteraemia were randomised open-label to cefazolin versus an antistaphylococcal penicillin (flucloxacillin/cloxacillin). On 90-day all-cause mortality cefazolin was noninferior, and it caused less acute kidney injury. Takeaway: reassurance for cefazolin as a first-line option in MSSA bacteraemia, with a cleaner renal profile where flucloxacillin nephrotoxicity is a concern.
Zorevunersen in Dravet syndrome (positive; first-in-class). An intrathecal antisense oligonucleotide that up-regulates Na₋1.1 channels to correct the underlying SCN1A defect. Earlier-phase open-label data showed median convulsive-seizure frequency falling roughly 85% at three months and 74% at six, with durable gains in cognition and behaviour — the first signal of disease modification, not just seizure suppression, in this catastrophic genetic epilepsy. The phase 3 EMPEROR trial is enrolling, with a readout targeted around 2027. Takeaway: a potential paradigm shift, pending confirmation.
Also in the issue: SirPAD (sirolimus-coated balloon angioplasty for infrainguinal peripheral-artery disease) and mavacamten in adolescents with obstructive HCM (SCOUT-HCM) round out the ahead-of-print cardiology; a randomised trial of endovascular stenting for post-thrombotic syndrome lands with a “step forward” editorial; plus a clinical review on differentiated thyroid cancer, perioperative enfortumab vedotin–pembrolizumab in muscle-invasive bladder cancer, and global-health correspondence on intravenous artesunate in artemisinin-resistant severe malaria in Uganda and Sudan virus disease.
Provenance: read this morning from Luca’s pinned NEJM current-issue eTOC feed (Vol 394, No 23, 18 June 2026) via Control Chrome; the second pinned NEJM tab (cardiology/ahead-of-print) was not open at run time, but the eTOC feed carried the ahead-of-print cardiology queue, and every result was cross-checked via web search against NEJM abstracts and ACC 2026 / ESC / Healio / TCTMD coverage. Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Sat 20Weekend — markets closed. Watch for a new date on the US–Iran Switzerland talks and the Lebanon ceasefire; G7/EU diplomatic follow-through
Mon 22US stock & bond markets reopen — first live read on post-Juneteenth positioning and the post-Warsh rate path · quiet data slate
Tue 23Flash PMIs — Germany, Eurozone, UK and US (June)
Wed 24Australia CPI
Thu 25US PCE price index (May) — the key inflation print under the hawkish Fed · final US Q1 GDP · Japan CPI · Australia jobs
WatchUS–Iran talks date & Lebanon · post-Warsh rate-hike pricing & the 10-year · oil’s Hormuz/Lebanon response · UK gilts & Burnham’s chancellor pick · US Section 301 pharma probe of Germany · AI IPO/bond supply (OpenAI, SpaceX, Anthropic)